In our cohort, SIGLEC-1 expression remained largely constant over time in SSc patients, even with increases or decreases in immunosuppressive therapy, including hydroxychloroquine or other drugs such as glucocorticoids, methotrexate, and rituximab which are known to decrease type-I IFN production. The gene discussed is SIGLEC1; the disease is systemic sclerosis.